[CYNO] Cynosure, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 43.65 Change: 1.45 (3.44%)
Ext. hours: Change: 0 (0%)

chart CYNO

Refresh chart

Description: Cynosure, Inc. develops, manufactures, and markets aesthetic treatment systems primarily to the dermatology, plastic surgery, and general medical markets. Its aesthetic treatment systems incorporate a range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:YAG, Er:YAG, Erbium:glass, CO2, and diode lasers, as well as intense pulsed light devices. The company?s aesthetic treatment systems comprise Elite product line for hair removal, treatment of facial, and leg veins and pigmentations; Smartlipo product line for LaserBodySculpting for the removal of unwanted fat; Cellulaze product line for the treatment of cellulite; SmoothShapes XV product line for the temporary reduction in the appearance of cellulite; Affirm/SmartSkin product line for anti-aging applications, including treatments for wrinkles, skin texture, skin discoloration, and skin tightening; Cynergy product line for the treatment of vascular lesions; and Accolade, MedLite C6, and RevLite product lines for the removal

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 3.22% Sales Growth - Q/Q-13.16% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA6.63% ROE8.52% ROI7.98%
Current Ratio3.06 Quick Ratio2.18 Long Term Debt/Equity0.1 Debt Ratio0.22
Gross Margin56.54% Operating Margin7.2% Net Profit Margin10.04% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities850 K Cash From Investing Activities240 K Cash From Operating Activities-4.76 M Gross Profit47.36 M
Net Profit5.36 M Operating Profit7.64 M Total Assets489.57 M Total Current Assets274.65 M
Total Current Liabilities77.63 M Total Debt17.09 M Total Liabilities105.88 M Total Revenue83.69 M
Technical Data
High 52 week66.3 Low 52 week33.77 Last close66 Last change0%
RSI57.14 Average true range4.8 Beta0.69 Volume376.36 K
Simple moving average 20 days-0.03% Simple moving average 50 days13.08% Simple moving average 200 days27.74%
Performance Data
Performance Week0% Performance Month-0.38% Performance Quart56.77% Performance Half25.64%
Performance Year79.93% Performance Year-to-date44.74% Volatility daily0.15% Volatility weekly0.33%
Volatility monthly0.67% Volatility yearly2.31% Relative Volume339.87% Average Volume1.12 M
New High New Low


2018-11-05 13:03:12 | Small Caps: Assessing Management Guidance and Analysts' Estimates

2017-03-24 14:00:35 | Can Anyone Challenge Allergan In Medical-Aesthetics Market?

2017-03-24 12:02:35 | Allergan Hoovers Aesthetics Market; Can Hologic Play?

2017-03-23 17:04:25 | CYNOSURE INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure t

2017-03-23 08:48:12 | Hologic Completes Cynosure Buyout, Boosts Core Business

2017-03-22 18:10:00 | Penn National Gaming Set to Join S&P SmallCap 600

2017-03-22 11:00:00 | MRLB U.S. Sales Jump 38% As Aesthetic Market Heats Up

2017-02-28 18:34:56 | CYNOSURE INC Files SEC form 10-K, Annual Report

2017-02-28 16:16:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Cynosure, Inc. - CYNO

2017-02-22 06:26:57 | CYNOSURE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits

2017-02-21 10:58:00 | Medtronic Earnings Rebound in Third Quarter, Shares Climb

2017-02-16 15:21:00 | INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Cynosure, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

2017-02-16 10:53:00 | CYNOSURE, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by Hologic, Inc. May be Unfair to Shareholders

2017-02-15 17:20:00 | Harwood Feffer LLP Announces Investigation of Cynosure, Inc.

2017-02-15 14:34:00 | SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Cynosure, Inc. And Encourages Investors To Contact The Firm For Additional Information

2017-02-15 11:01:00 | Hologic to Acquire Cynosure for $1.65 Billion

2017-02-15 09:30:02 | Cynosure CYNO to be Acquired by Hologic in $1.65B Deal

2017-02-14 18:42:00 | CYNOSURE, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

2017-02-14 17:26:05 | CYNOSURE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws

2017-02-14 16:53:41 | Dr Pepper Snapple and Popeyes sink; General Motors leaps

2017-02-14 16:41:00 | Why Cynosure, RetailMeNot, and TransUnion Jumped Today

2017-02-14 16:09:19 | Hologic Follows Allergan, Buying Body-Sculptor Cynosure For $1.65 Bil

2017-02-14 15:40:23 | ETFs with exposure to Cynosure, Inc. : February 14, 2017

2017-02-14 11:58:56 | Here's Why Cynosure, Inc. is Soaring Today

2017-02-14 11:48:44 | Hologic to buy Cynosure to expand into medical aesthetics

2017-02-14 11:05:09 | Hologic will snap up Westford-based Cynosure in $1.65B deal

2017-02-14 10:46:19 | Hologic Follows Allergan, Buying Body-Sculptor Cynosure For $1.65 Bil

2017-02-14 10:03:11 | Hologic buys Cynosure to expand into medical aesthetics

2017-02-14 09:55:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Cynosure, Inc. for $66 Per Share is Fair to Shareholders - CYNO

2017-02-14 09:45:08 | Hologic will snap up Westford-based Cynosure in $1.65B deal

2017-02-14 09:29:09 | Cynosure's stock rockets after buyout deal with Hologic

2017-02-14 09:07:00 | CYNOSURE CYNO Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of Cynosure, Inc.

2017-02-14 08:10:34 | Hologic to buy Cynosure for $1.65 bln

2017-02-14 08:00:00 | Hologic to Acquire Cynosure, Leader in Medical Aesthetics Systems and Technologies, in All-Cash Tender Offer that Combines Two Complementary Businesses

2017-02-09 12:05:23 | Cynosure, Inc. :CYNO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 9, 2017

2017-02-08 12:38:21 | Cynosure, Inc. :CYNO-US: Earnings Analysis: 2016 By the Numbers : February 8, 2017

2017-02-07 11:59:44 | Edited Transcript of CYNO earnings conference call or presentation 7-Feb-17 2:00pm GMT

2017-02-07 08:47:46 | Cynosure beats Street 4Q forecasts

2017-02-07 08:40:01 | Implied Volatility Surging for Cynosure CYNO Stock Options

2017-02-07 08:08:28 | CYNOSURE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2017-02-07 08:00:00 | Cynosure Achieves Record Quarterly Revenue of $122.1 Million in the Fourth Quarter of 2016, Up 19 Percent Year-over-Year

2017-02-07 07:07:04 | Q4 2016 Cynosure Inc Earnings Release - Before Market Open

2017-02-01 16:36:53 | Cynosure, Inc.: Leads amongst peers with strong fundamentals

2017-01-27 06:14:38 | CYNOSURE INC Files SEC form 8-K, Other Events

2017-01-24 08:30:01 | Cynosure CYNO Looks Good: Stock Adds 6.6% in Session

2017-01-24 07:22:07 | Cynosure, Inc. breached its 50 day moving average in a Bullish Manner : CYNO-US : January 24, 2017

2017-01-23 17:45:00 | Why Northern Dynasty Minerals, Cynosure, and Viavi Solutions Jumped Today

2017-01-23 16:44:43 | Cynosure soars on deal talk; Qualcomm slumps on Apple suit

2017-01-23 11:59:28 | Why Cynosure, Inc. Is Rising Today

2017-01-23 09:01:00 | Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open